Qin Yuan, Song Ning-Hong, Ye He-Song, Tang Long-Long, Yang Ming, Gong Wen-Tao, He Qi, Zhang Wei
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Department of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine / The Second Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210017, China.
Zhonghua Nan Ke Xue. 2020 Nov;26(11):1025-1029.
To investigate the effect of Linshu Decoction (LSD) combined with levofloxacin in the treatment of lower urinary tract symptoms in patients with type ⅢA prostatitis.
We randomly divided 124 type ⅢA prostatitis patients with lower urinary tract symptoms into an experimental and a control group, the former treated orally with LSD (1 dose bid) combined with levofloxacin tablets (0.1 g bid), and the latter with levofloxacin tablets only (0.1g bid). Before and after 4 weeks of medication, we obtained the NIH-CPSI, Traditional Chinese Medicine symptoms (TCM) scores, white blood cell (WBC) count in EPS and the results of uroflowmetry from the patients and compared them between the two groups.
Finally 115 of the patients were included in this study. After 4 weeks of treatment, the patients of the experimental group, compared with the controls, showed significantly decreased NIH-CPSI (14.57 ± 3.87 vs 20.12 ± 3.45, P < 0.05), TCM scores (6.35 ± 1.27 vs 10.72 ± 1.72, P < 0.05) and WBC count in EPS ([7.35 ± 4.52] vs [9.87 ± 5.87] n/HP, P < 0.05). In comparison with baseline, the maximum urinary flow rate (Qmax) and average urinary flow rate (Qave) were increased in both of the two groups after medication, with statistically significant difference only in the experimental group (P < 0.05).
Linshu Decoction combined with levofloxacin is more effective than levofloxacin alone in the treatment of lower urinary tract symptoms in patients with type ⅢA prostatitis.
探讨淋舒汤联合左氧氟沙星治疗ⅢA 型前列腺炎患者下尿路症状的效果。
将 124 例伴有下尿路症状的ⅢA 型前列腺炎患者随机分为试验组和对照组,试验组口服淋舒汤(1 剂,每日 2 次)联合左氧氟沙星片(0.1 g,每日 2 次),对照组仅口服左氧氟沙星片(0.1 g,每日 2 次)。用药 4 周前后,获取患者的美国国立卫生研究院前列腺炎症状指数(NIH-CPSI)、中医症状评分、前列腺液白细胞(WBC)计数及尿流率结果,并在两组间进行比较。
最终 115 例患者纳入本研究。治疗 4 周后,试验组患者与对照组相比,NIH-CPSI 显著降低(14.57±3.87 比 20.12±3.45,P<0.05),中医症状评分降低(6.35±1.27 比 10.72±1.72,P<0.05),前列腺液 WBC 计数降低([7.35±4.52]比[9.87±5.87]个/高倍视野,P<0.05)。与基线相比,两组用药后最大尿流率(Qmax)和平均尿流率(Qave)均升高,仅试验组差异有统计学意义(P<0.05)。
淋舒汤联合左氧氟沙星治疗ⅢA 型前列腺炎患者下尿路症状比单用左氧氟沙星更有效。